Merck & Co., Inc. (NYSE:MRK) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

Merck & Co., Inc. (NYSE:MRK) had its price target hoisted by research analysts at The Goldman Sachs Group from $140.00 to $160.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s price target would suggest a potential upside of 5.39% from the company’s previous close.

MRK has been the topic of a number of other reports. Royal Bank Of Canada downgraded shares of Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and increased their price objective for the company from $142.00 to $150.00 in a research note on Thursday. Jefferies Financial Group cut Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. UBS Group lifted their target price on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday. Wall Street Zen downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Finally, Guggenheim increased their price target on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Fifteen analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $144.10.

Merck & Co., Inc. Trading Up 1.9%

Shares of Merck & Co., Inc. stock traded up $2.83 on Friday, hitting $151.82. 8,557,185 shares of the company traded hands, compared to its average volume of 10,815,531. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The company has a market cap of $374.57 billion, a PE ratio of 121.46, a PEG ratio of 6.56 and a beta of 0.19. The stock’s 50 day moving average price is $127.43 and its 200-day moving average price is $121.01. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $154.49.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.Merck & Co., Inc.’s revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities research analysts predict that Merck & Co., Inc. will post 2.77 EPS for the current year.

Insider Activity at Merck & Co., Inc.

In other news, EVP David R. Maraldo sold 18,706 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the sale, the executive vice president owned 18,212 shares of the company’s stock, valued at $2,344,248.64. The trade was a 50.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP David Michael Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 228,238 shares of company stock valued at $29,977,783 in the last three months. Company insiders own 0.17% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Brighton Jones LLC grew its stake in shares of Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after acquiring an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC grew its stake in Merck & Co., Inc. by 52.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after purchasing an additional 3,941 shares in the last quarter. Diversify Advisory Services LLC raised its position in Merck & Co., Inc. by 94.1% in the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock valued at $2,590,000 after purchasing an additional 15,636 shares in the last quarter. Diversify Wealth Management LLC increased its holdings in Merck & Co., Inc. by 22.2% in the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock valued at $3,054,000 after buying an additional 6,897 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Merck & Co., Inc. by 111.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock valued at $53,918,000 after buying an additional 359,356 shares in the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Phase 3 cancer-vaccine success: Merck and Moderna reported that their personalized mRNA vaccine, used with Merck’s Keytruda, improved recurrence-free and distant metastasis-free survival in high-risk melanoma patients versus Keytruda alone. It is the first positive late-stage result for an mRNA cancer vaccine and supports a potential regulatory filing aimed at approval as early as 2027. MRK/MRNA’s Personalized Cancer Therapy Delivers First Phase III Win
• Positive Sentiment: Analyst support strengthened: Morgan Stanley upgraded MRK to overweight and raised its price target to $179, while UBS lifted its target to $175 with a buy rating. BMO also raised its target to $170 and maintained an outperform rating, reflecting greater confidence in Merck’s oncology opportunity. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Positive Sentiment: Pipeline diversification: Merck’s newer medicines, acquired assets and product launches are gaining traction and could help cushion revenue pressure when Keytruda loses exclusivity, expected in 2028. Can Merck’s New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
• Neutral Sentiment: Unusually high options activity indicates elevated investor interest and potential near-term volatility, but it does not by itself change Merck’s fundamentals. Merck & Co., Inc. Target of Unusually High Options Trading
• Negative Sentiment: Valuation and patent risk: RBC downgraded MRK to sector perform with a $150 target, arguing that the stock’s sharp rally has produced an unusually high valuation for a company facing Keytruda’s loss of exclusivity in roughly two years. Jefferies separately moved the shares to hold. Merck’s Cancer-Vaccine Trial Results Surpassed Expectations – So, Why Did RBC Downgrade MRK Stock?
• Negative Sentiment: Execution remains ahead: The vaccine still requires regulatory approval, commercial launch and successful expansion beyond melanoma; analysts caution that the trial win alone does not yet offset the longer-term Keytruda revenue risk.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.